The trial of the Oxford AstraZeneca COVID-19 vaccine in children continues with no safety concerns, new vaccinations were briefly delayed as we awaited the outcome of a review by the Medicines and Healthcare products Regulatory Agency (MHRA) of very rare and unusual blood clots in adults.
The MHRA concluded its review of these very rare events and did not recommend any age restriction on the use of the vaccine. (MHRA Statement)
The Joint Committee on Vaccination and Immunisation, who provide scientific advice to the Department of Health, has suggested that on a precautionary basis, adults under 30 who are still unvaccinated should be offered an alternative Covid-19 vaccine, if available. (JCVI Statement)
Following this recommendation, no additional children are being recruited but all other study visits continue as planned for those enrolled. We will continue to review safety data from the national roll out, and the clinical trials, with the MHRA and the trial’s Data Safety monitoring board Parents and our young trial volunteers can contact their trial site for further information